Read by QxMD icon Read


Huangming Hong, Xiaojie Fang, Zhao Wang, He Huang, Sio Teng Lam, Fangfang Li, Chen Peng, Ying Tian, Suxia Lin, Tongyu Lin
Angioimmunoblastic T-cell lymphoma (AITL) is a distinct subtype of peripheral T-cell lymphoma with unique clinical and pathological features. This study aim to design a prognostic model specifically for AITL, providing risk stratification in affected patients. A total of 115 newly diagnosed AITL patients were retrospectively analyzed. The estimated five-year overall survival (OS) rate for all patients was 45.4%. Multivariate analysis found prognostic factors for survival were bone marrow involvement, number of extranodal sites >1, and performance status >1...
June 18, 2018: Leukemia & Lymphoma
Cristiane R Ferreira, Shuchun Zhao, Malaya K Sahoo, Benjamin Pinsky, Jenna Weber, Luis A P C Lage, Juliana Pereira, Maria C N Zerbini, Yasodha Natkunam
Forkhead box P3 (FOXP3) is a specific marker for regulatory T-cells (Tregs). We report 6 cases of T-cell lymphomas with Treg phenotype based on diffuse positivity for FOXP3 in tumor cells. The patients showed a median age of 56years with a male predominance. Sites of disease included lymph nodes (4), skin (2), subcutaneous tissue (1) and bone marrow (1). All cases showed monomorphic large cells, some with Hodgkin-like or anaplastic cells. All cases expressed pan T cell markers and lacked cytotoxic markers; one case showed diffuse PD1 staining...
June 10, 2018: Human Pathology
Chien Ing Yeo, Kah Kooi Ooi, Edward R T Tiekink
A new era of metal-based drugs started in the 1960s, heralded by the discovery of potent platinum-based complexes, commencing with cisplatin [(H₃N)₂PtCl₂], which are effective anti-cancer chemotherapeutic drugs. While clinical applications of gold-based drugs largely relate to the treatment of rheumatoid arthritis, attention has turned to the investigation of the efficacy of gold(I) and gold(III) compounds for anti-cancer applications. This review article provides an account of the latest research conducted during the last decade or so on the development of gold compounds and their potential activities against several cancers as well as a summary of possible mechanisms of action/biological targets...
June 11, 2018: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
Jin Zhao, Fuming Chen, Yutong Han, Huaqing Chen, Zhidong Luo, Hao Tian, Yi Zhao, Aiqing Ma, Longguan Zhu
Three new crystal structures containing [PtCl₆]2− , pyridinium and benzimidazole groups have been prepared: [PtCl₆]·(H-bzm)₂·2(H₂O) ( 1 ), [PtCl₆]·(H-bipy)₂·2(H₂O) ( 2 ), [PtCl₆]·(H-dimethyl-bipy)₂·2(H₂O) ( 3 ) [H-bzm: benzimidazole cation, H-bipy: 2,2′-bipyridine cation, H-dimethyl-bipy: 4,4′-bimethyl-2,2′-bipyridine cation]. All compounds have been fully characterized by elemental analyses, single-crystal X-ray analyses, IR spectra, TG analyses, and fluorescence studies...
June 8, 2018: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
Daisuke Yamashita, Kazuyuki Shimada, Katsuyoshi Takata, Tomoko Miyata-Takata, Kei Kohno, Akira Satou, Ayako Sakakibara, Shigeo Nakamura, Naoko Asano, Seiichi Kato
Nodal cytotoxic molecule (CM)-positive peripheral T-cell lymphoma (CTL) has recently been recognized as a clinicopathologically distinct disease. To further characterize this disease, here we compared 58 patients with Epstein-Barr virus (EBV)-negative CTL to 48 patients with EBV-positive CTL. The two groups did not differ in histopathology, T-cell receptor (TCR) expression or rearrangement incidences, or survival curves. However, patients with EBV-negative CTL less frequently showed hepatic involvement (P = 0...
May 29, 2018: Cancer Science
Osamu Imataki, Makiko Uemura
Background: Chronic lymphocytic leukemia (CLL) is a mature lymphoid neoplasm currently categorized as an indolent type of malignant lymphoma. CLL progresses slowly over years, but it eventually transforms to a more aggressive lymphoma such as the diffuse large B-cell (DLBCL) type, also known as Richter's syndrome. Case presentation: We treated a 69-year-old Japanese male who was histologically diagnosed with Richter's syndrome after 6 years of CLL. His lymphadenopathy had systemically progressed for years, with lymphocyte counts of less than 10,000 cells/μL and a disease status of Rai classification stage I and Binet classification B...
2018: BMC Clinical Pathology
Kenichi Mizutani, Sohsuke Yamada, Xin Guo, Chizuru Futatsuya, Motona Kumagai, Akihiro Shioya, Akane Aikawa, Satoko Nakada, Nozomu Kurose, Hiroshi Minato, Takayuki Nojima
BACKGROUND: The occurrence of malignant lymphoma after delivery is an extremely rare event. Although several cases of Hodgkin lymphoma and B cell lymphoma and a few cases of peripheral T cell lymphoma (PTCL) after delivery have been reported, there are no report of autopsy cases of PTCL in the puerperal period. CASE PRESENTATION: A 32-year-old Japanese woman with a past medical history of atopic dermatitis and bronchial asthma presented with generalized eruptions four days after the delivery of her first child; generalized skin induration and lymphadenopathy subsequently emerged...
May 22, 2018: Diagnostic Pathology
Eriko Yanagida, Hiroaki Miyoshi, Keisuke Kawamoto, Kazutaka Nakashima, Kotaro Matsuda, Kyohei Yamada, Reiji Muto, Koji Nagafuji, Masao Seto, Koichi Ohshima
Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is cytologically and phenotypically heterogeneous. Retinoic acid-related orphan receptor-γt (RORγt) is a transcription factor that regulates the differentiation of naïve CD4+ helper T-cells to Th17 cells. In the present study, we immunohistochemically confirmed the expression of RORγt in PTCL-NOS. Pathological and clinical investigations were performed for 170 cases of PTCL-NOS. RORγt-positive cases accounted for 17.6% (30/170) of the total cases and they showed a significantly higher frequency of CD8 positivity (P=...
May 15, 2018: Human Pathology
Anders Reinholdt, Anthony F Hill, Jesper Bendix
The sterically accessible carbide complex, (Cy3P)Cl3Ru[triple bond, length as m-dash]C-PtCl(py)2, acts as a synthon for terminal and bridging carbide fragments that relocate to pincer and A-frame scaffolds upon ligand addition. This concept, benefitting from coordination sphere selection as the concluding step, confronts traditional synthetic strategies and broadens the scope for carbide complexes.
May 18, 2018: Chemical Communications: Chem Comm
Samuel Y Ng, Leon Brown, Kristen Stevenson, Tiffany deSouza, Jon C Aster, Abner Louissaint, David M Weinstock
Patients with angioimmunoblastic T-cell lymphoma (AITL) and other peripheral T-cell lymphomas (PTCL) that harbor features of follicular helper T (TFH) cells have a very poor prognosis. These lymphomas commonly present with paraneoplastic autoimmunity and lymphopenia. RhoA G17V mutation is present in 60% of TFH-like lymphomas but its role in tumorigenesis is poorly understood. We generated transgenic mice that express RhoA G17V under the control of murine CD4 regulatory elements at levels comparable to a heterozygous mutation (tgRhoA mice)...
May 16, 2018: Blood
Kamel Laribi, Mustapha Alani, Catherine Truong, Alix Baugier de Materre
OBJECTIVE: Mature T-cell lymphomas are a heterogeneous group of T-cell malignancies with a poor outcome. The discovery of new molecular biomarkers has led to the emergence of new drugs in recent years that target various signaling pathways. METHOD: We examined all pertinent published patents through 2015 that analyzed novel methods for the diagnosis and treatment of T cell lymphoma, as well as related published and unpublished studies. Selection criteria were established before data collection...
May 16, 2018: Recent Patents on Anti-cancer Drug Discovery
Violeta Sicilia, Lorenzo Arnal, Sara Fuertes, Antonio Martín
New bis-pyrazole complexes [Pt(C^C*)(RpzH)2]X, containing a cyclometalated N-heterocyclic carbene ligand (HC^C* = 1-(4-(ethoxycarbonyl)phenyl)-3-methyl-1H-imidazol-2-ylidene) were prepared as chloride (X = Cl-, RpzH: 3,5-Me2pzH 1a, 4-MepzH 2a, pzH 3a), perchlorate (X = ClO4-,1b  3b), or hexafluorophosphate (X = PF6-, RpzH: 3,5-Me2pzH 1c) salts. The X-ray structure of 1a showed that the Cl- anion is trapped by the cation through two N-H***Cl bonds. In solution of methanol, acetone and THF at r.t. 1a-3a, coexist in equilibrium with the corresponding [PtCl(C^C*)(RpzH)](B) and RpzH species...
May 15, 2018: Chemistry: a European Journal
E Matutes
Over the last decade, there has been a significant body of information regarding the biology of the lymphoid neoplasms. This clearly supports the need for updating the 2008 WHO (World Health Organization) classification of haematopoietic and lymphoid tumours. The 2017 WHO classification is not a new edition but an update and revision of the 4th edition. New provisional entities but not new definitive entities are included, and novel molecular data in most of the entities and changes in the nomenclature in few of them have been incorporated...
May 2018: International Journal of Laboratory Hematology
Takuto Sueyasu, Kazunori Tobino, Masanobu Okahisa, Kojin Murakami, Yuki Goto, Miyuki Munechika, Kohei Yoshimine, Saori Nishizawa, Yuki Ko, Yuki Yoshimatsu, Mina Asaji, Kosuke Tsuruno, Hiromi Ide, Hiroyuki Miyajima
Peripheral T cell lymphoma not otherwise specified (PTCL-NOS) is a rare entity of lymphoma. We herein report an even rarer case of a 68-year-old male with PTCL-NOS presenting as an endobronchial lesion, and review previously published cases in the literature. Initially, he was referred to our hospital for further investigation of the right upper lobe consolidation on chest radiograph. Computed tomography and 18F-fludeoxyglucose positron emission tomography revealed a right hilar mass with obstruction of the main bronchus and submandibular, right axillary and mediastinal lymphadenopathy...
2018: Respiratory Medicine Case Reports
Shinichi Makita, Akiko Miyagi Maeshima, Dai Maruyama, Koji Izutsu, Kensei Tobinai
T-cell lymphoma is a rare hematologic malignancy with an incidence rate between 10% and 20% of that of non-Hodgkin lymphomas. Patients with peripheral T-cell lymphoma (PTCL) generally have a poor prognosis when treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP)/CHOP-like chemotherapy; once relapse occurs, it is mostly regarded as an incurable disease. To overcome the chemorefractoriness of PTCL, several novel agents have been developed. Since the first approval of pralatrexate, a dihydrofolate reductase inhibitor, for relapsed/refractory PTCL by the US Food and Drug Administration, several new agents, such as romidepsin (histone deacetylase inhibitor), brentuximab vedotin (antibody-drug conjugate targeting CD30), chidamide (histone deacetylase inhibitor), and mogamulizumab (anti-CC chemokine receptor 4 monoclonal antibody), have been approved as a therapeutic option for relapsed/refractory PTCL in several countries, including the US, Europe, China, and Japan...
2018: OncoTargets and Therapy
Norbert Schmitz, Georg Lenz, Matthias Stelljes
Mature T-and natural killer cell (NK) - cell neoplasms comprise a group of morphologically, immunophenotypically, molecularly, and clinically heterogeneous disorders with generally unfavorable outcome. Results of first-line chemotherapy are unsatisfactory for the most common T-cell lymphomas (PTCL-NOS; AITL; ALCL, ALK-negative) as well as for many other entities. High-dose therapy followed by autologous hematopoietic stem cell transplantation is widely recommended for consolidation after a complete or partial remission is achieved...
April 26, 2018: Blood
Anna Maroń, Katarzyna Czerwińska, Barbara Machura, Luis Raposo, Catarina Roma-Rodrigues, Alexandra R Fernandes, Jan G Małecki, Agata Szlapa-Kula, Slawomir Kula, Stanisław Krompiec
Structural, spectroscopic and electrochemical properties of six complexes [AuCl(L1)](PF6)2·CH3CN (1), [AuCl(L2)](PF6)2 (2), [PtCl(L1)](BPh4)·CH3CN (3), [PtCl(L2)](SO3CF3) (4), [CuCl2(L1)] (5) and [CuCl2(L2)]·CH3CN (6) with modified 2,2':6',2''-terpyridine ligands, 4'-(4-methoxyphenyl)-2,2':6',2''-terpyridine (L1) and 4'-(4-methoxynaphthalen-1-yl)-2,2':6',2''-terpyridine (L2) were thoroughly investigated and a significant role of the substituent (4-methoxyphenyl or 4-methoxynaphthalen-1-yl) and the metal center was demonstrated...
May 8, 2018: Dalton Transactions: An International Journal of Inorganic Chemistry
Adam J Olszewski, Thomas Ollila, John L Reagan
In aggressive lymphomas, discrepancies in survival reported from experimental and observational studies may reflect selective non-enrolment of high-risk patients in trials. We examined the association between time from diagnosis to chemotherapy and overall survival in diffuse large B-cell (DLBCL), Burkitt (BL), mantle cell (MCL) and peripheral T-cell lymphoma (PTCL), using National Cancer Data Base records of 130 549 patients treated in 2004-2014. Across the histologies, patients who started chemotherapy within 7 days of diagnosis had more often high International Prognostic Index (IPI) or advanced-stage disease...
May 2018: British Journal of Haematology
Michael Markow, Abu-Sayeef Mirza, Lia Perez, Haipeng Shao, Pedro Horna, Claudio Anasetti, Lubomir Sokol, Mohammad O Hussaini
Nonhepatosplenic/noncutaneous γδ peripheral T-cell lymphoma (NHNC γδ PTCL) represents a miscellaneous group of unrelated T-cell lymphomas of which only isolated cases have been reported. We describe two cases of transformation from T-lymphoblastic leukemia/lymphoma to NHNC γδ PTCL. Transformation into more aggressive disease is a rare event in T-cell lineage-derived hematologic malignancies compared to B-cell neoplasms. Nevertheless, both of our cases involved relapse as PTCL manifested with skin involvement and an overt shift from blastic morphology to large granular leukemia-like mature T cells...
2018: Case Reports in Hematology
Haley M Simpson, Aki Furusawa, Kavitha Sadashivaiah, Curt I Civin, Arnob Banerjee
Peripheral T-cell lymphoma (PTCL) is a rare, aggressive, heterogeneous, Non-Hodgkin's lymphoma with poor prognosis and inadequate response to current therapies. Recent sequencing studies indicate a prevalence of activating mutations in the JAK/STAT signaling pathway. Oncogenic mutations in STAT5B, observed in approximately one third of cases of multiple different PTCL subtypes, correlate with inferior patient outcomes. Therefore, interest in the development of therapeutic strategies for targeting STAT5 in PTCL is warranted...
March 30, 2018: Oncotarget
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"